Accustem Sciences (Accustem Sciences) Debt-to-EBITDA : -0.06 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Accustem Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.06 Mil. Accustem Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Accustem Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.98 Mil. Accustem Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Accustem Sciences's Debt-to-EBITDA or its related term are showing as below:

ACUT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.03 Med: -0.03 Max: -0.03
Current: -0.03

During the past 2 years, the highest Debt-to-EBITDA Ratio of Accustem Sciences was -0.03. The lowest was -0.03. And the median was -0.03.

ACUT's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs ACUT: -0.03

Accustem Sciences Debt-to-EBITDA Historical Data

The historical data trend for Accustem Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Debt-to-EBITDA Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Debt-to-EBITDA

-0.03

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.03	-	-0.20	-0.05	-0.06

Competitive Comparison of Accustem Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Accustem Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Debt-to-EBITDA falls into.

Accustem Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Accustem Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.056	+	0)	/	-2.047
	=	-0.03

Accustem Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.056	+	0)	/	-0.98
	=	-0.06

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Accustem Sciences (OTCPK:ACUT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Accustem Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences (Accustem Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001

Website

http://www.accustem.com

Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.